HealthQuill DIOSynVax
UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza viruses.
Drugs Health Medical

UK’s DIOSynVax develops single candidate vaccine for bird flu virus

UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza.

Read More
DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of an antigen-based vaccine candidate to treat all coronaviruses.
Drugs Health Pharma

DIOSynVax to finish coronavirus vaccine trial in humans by month-end

HQ Team September 29, 2023: DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of.

Read More